JAZZ GS CB TIF AXP PLL UHS NKE LIFE DHR WCG PVH PCLN TRV LLL PRU APH LEA HON UTX MON UPS V BWA WCC AMP AMZN MCK MCK FDX WHR FDX WHR UNP INTU COF ROC URI AET AIZ FRX LTD LNC GRA ABC STT STT
Amarin Corporation plc (Amarin) is a late-stage biopharmaceutical -company with expertise in lipid science focused on the treatment of cardiovascular disease. The Companyï¿½s product candidate is AMR101, an ultra-pure omega-3 fatty acid. It is developing AMR101 for the treatment of patients with high triglyceride levels, or hypertriglyceridemia. In September 2011, it filed a New Drug Application (NDA), with the United States Food and Drug Administration (FDA). In December 2011, it commenced patient dosing in its cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with eicosapentanoic acid (EPA) - Intervention Trial).